United States · Bill · HR
H.R. 5926 (115th)
Naloxone Guidelines Act of 2018
Introduced
23 May 2018
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
11 August 2025
Summary
Naloxone Guidelines Act of 2018 This bill requires the Department of Health and Human Services to issue guidelines for prescribing an opioid overdose reversal drug (e.g., naloxone). The guidelines must address issues relating to the distribution, education, and safety of opioid overdose reversal drugs, including: co-prescription with an opioid; safe dosages; prescription for non-patients; and standing orders (i.e., orders that allow dispensing without a prescription).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 23 May 2018
Introduced in House (PDF)
Introduced in House · EN · 23 May 2018
Introduced in House
summary · EN · 23 May 2018
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/115th-congress/house-bill/5926
- Open data entity: https://api.congress.gov/v3/bill/115/hr/5926